CONBRIZA
Land: Israel
Sprog: engelsk
Kilde: Ministry of Health
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
BAZEDOXIFENE AS ACETATE 20 MG
Tilgængelig fra:
NEOPHARM LTD
ATC-kode:
G03XC02
Lægemiddelform:
COATED TABLETS
Indgivelsesvej:
PER OS
Fremstillet af:
PFIZER IRELAND PHARMACEUTICALS
Terapeutisk gruppe:
BAZEDOXIFENE
Terapeutiske indikationer:
CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit
Autorisation dato:
2013-04-01
